Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective
Authors
Keywords
-
Journal
CLINICAL INFECTIOUS DISEASES
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-01-04
DOI
10.1093/cid/ciab1070
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic potential of Fosmanogepix (APX001) for intra-abdominal candidiasis: from lesion penetration to efficacy in a mouse model
- (2021) Annie Lee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date
- (2021) Rhonda E Colombo et al. EXPERT OPINION ON PHARMACOTHERAPY
- Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
- (2021) Sabelle Jallow et al. Journal of Fungi
- Review of T-2307, an Investigational Agent That Causes Collapse of Fungal Mitochondrial Membrane Potential
- (2021) Nathan P. Wiederhold Journal of Fungi
- Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In Vitro Activity against Members of the Fusarium oxysporum and Fusarium solani Species Complexes
- (2021) Hamid Badali et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ibrexafungerp Demonstrates In Vitro Activity against Fluconazole-Resistant Candida auris and In Vivo Efficacy with Delayed Initiation of Therapy in an Experimental Model of Invasive Candidiasis
- (2021) Nathan P. Wiederhold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antifungal Susceptibility Profiles of Olorofim (Formerly F901318) and Currently Available Systemic Antifungals against Mold and Yeast Phases of Talaromyces marneffei
- (2021) Jing Zhang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies
- (2021) Olga Rivero-Menendez et al. Journal of Fungi
- When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis
- (2021) Teny M. John et al. Journal of Fungi
- Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303)
- (2021) Jane R Schwebke et al. CLINICAL INFECTIOUS DISEASES
- Resistance to Antifungal Drugs
- (2021) Ronen Ben-Ami et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018–2019)
- (2021) Michael A. Pfaller et al. Journal of Global Antimicrobial Resistance
- Expanded access use of rezafungin for salvage therapy of invasive Candida glabrata infection: A case report
- (2021) Alina Adeel et al. Open Forum Infectious Diseases
- The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models
- (2021) Melanie T. Cushion et al. Journal of Fungi
- Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo‐controlled superiority study (VANISH 306)
- (2021) R Sobel et al. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
- (2021) Martin Hoenigl et al. DRUGS
- Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY Program 2016-2018
- (2020) Michael A. Pfaller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rezafungin In Vitro Activity against Contemporary Clinical Nordic Candida Isolates and Candida auris Determined by the EUCAST Reference Method
- (2020) Marie Helleberg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Enhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility
- (2020) Sean D. Liston et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-D-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis
- (2020) Vidmantas Petraitis et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus
- (2020) Teclegiorgis Gebremariam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and tolerability of a novel oral formulation of amphotericin B: Phase I EnACT Trial
- (2020) Caleb Skipper et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination
- (2020) Karin Meinike Jørgensen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Manogepix (APX001A) in vitro activity against Candida auris. A head to head comparison of EUCAST and CLSI MICs.
- (2020) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Aspergillus fumigatus and pan-azole resistance: who should be concerned?
- (2020) Nathan P. Wiederhold et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?
- (2020) Maria Aigner et al. Journal of Fungi
- Review of the Novel Investigational Antifungal Olorofim
- (2020) Nathan P. Wiederhold Journal of Fungi
- A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis
- (2020) Stephen R Brand et al. CLINICAL INFECTIOUS DISEASES
- Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis- The STRIVE Trial
- (2020) George R Thompson et al. CLINICAL INFECTIOUS DISEASES
- In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies
- (2020) Olga Rivero-Menendez et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data
- (2020) Yanan Zhao et al. Journal of Fungi
- Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections
- (2020) Karen Joy Shaw et al. Journal of Fungi
- Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Non-neutropenic Rabbits
- (2020) Ruta Petraitiene et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia
- (2020) Lynn Miesel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent
- (2020) Lindsey Cass et al. Pharmacology Research & Perspectives
- In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies
- (2019) Olga Rivero-Menendez et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies
- (2019) Olga Rivero-Menendez et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease
- (2019) S. Seyedmousavi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017
- (2019) M. A. Pfaller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis
- (2019) Andrej Spec et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ibrexafungerp: A novel oral glucan synthase inhibitor
- (2019) M R Davis et al. MEDICAL MYCOLOGY
- Therapeutic challenges of non-Aspergillus invasive mold infections in immunosuppressed patients
- (2019) Frederic Lamoth et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
- (2019) Nathan P. Wiederhold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
- (2019) Mili Kapoor et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis
- (2019) Sondus Alkhazraji et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents
- (2019) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model
- (2019) Annie Lee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis
- (2018) Stephen R. Brand et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- The effect of the novel antifungal drug F901318 (Olorofim) on the growth and viability of Aspergillus fumigatus
- (2018) Saskia du Pré et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- EUCAST Determination of olorofim (F901318) susceptibility of mould species, method validation and MICs
- (2018) Karin Meinike Jørgensen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Orotomide Olorofim is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis
- (2018) Nathan P. Wiederhold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
- (2018) Justin C. Bader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis
- (2018) M. Ghannoum et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The antifungal arsenal: alternative drugs and future targets
- (2018) Nathan P. Wiederhold INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Changes in the epidemiological landscape of invasive candidiasis
- (2018) Frederic Lamoth et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species
- (2018) Nathan P Wiederhold et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model
- (2018) Christopher L Hager et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions
- (2018) Stephen Wring et al. JOURNAL OF CLINICAL PHARMACOLOGY
- APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method
- (2018) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of novel antifungal compound APX001A against a large collection of Candida auris
- (2018) Elizabeth L Berkow et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei
- (2018) Michaela Lackner et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- SCY-078, A Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections During Mass Balance Studies with IV and PO 14C-SCY-078 in Albino and Pigmented Rats
- (2018) Stephen Wring et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Fungal Cyp51 Specific Inhibitor VT-1598 Demonstrates In vitro and In vivo Activity against Candida auris
- (2018) Nathan P. Wiederhold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata
- (2017) Nathan P Wiederhold et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates
- (2017) J. B. Buil et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans
- (2017) Nathan P. Wiederhold et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The Candida auris Alert: Facts and Perspectives
- (2017) Frederic Lamoth et al. JOURNAL OF INFECTIOUS DISEASES
- Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus
- (2017) Clara E Negri et al. JOURNAL OF INFECTIOUS DISEASES
- The antifungal pipeline: a reality check
- (2017) John R. Perfect NATURE REVIEWS DRUG DISCOVERY
- Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
- (2016) Taylor Sandison et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds
- (2016) W. A. Schell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, againstCandidaandAspergillusspp., including echinocandin- and azole-resistant isolates
- (2016) Michael A. Pfaller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The anti-Aspergillusdrug pipeline: Is the glass half full or empty?: Table 1.
- (2016) Nir Osherov et al. MEDICAL MYCOLOGY
- F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
- (2016) Jason D. Oliver et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antifungal Activities of SCY-078 (MK-3118) and Standard Antifungal Agents against Clinical Non-Aspergillus Mold Isolates
- (2015) Frédéric Lamoth et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species
- (2015) M.A. Pfaller et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Incidence Density of Invasive Fungal Infections during Primary Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Patients in a Tertiary Cancer Center, 2009 to 2011
- (2013) Marisa Z. R. Gomes et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Inhibiting GPI Anchor Biosynthesis in Fungi Stresses the Endoplasmic Reticulum and Enhances Immunogenicity
- (2012) Catherine A. McLellan et al. ACS Chemical Biology
- In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods
- (2012) M. A. Pfaller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis
- (2011) Katsura Hata et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
- (2011) Mamiko Miyazaki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods
- (2011) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- An insight into the antifungal pipeline: selected new molecules and beyond
- (2010) Luis Ostrosky-Zeichner et al. NATURE REVIEWS DRUG DISCOVERY
- An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients
- (2009) C. Viscoli et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of MGCD290, a Hos2 Histone Deacetylase Inhibitor, in Combination with Azole Antifungals against Opportunistic Fungal Pathogens
- (2009) M. A. Pfaller et al. JOURNAL OF CLINICAL MICROBIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started